1,4-dihydroquinoxaline | 875290-35-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 英文名称: 1,4-dihydroquinoxaline
• 英文别名: 1,4-Dihydro-chinoxalin
• CAS: 875290-35-0
• 化学式: C₈H₈N₂
• mdl: MFCD19217299
• 分子量: 132.165
• InChiKey: LPMASUTYBHSHIC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  10
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  24.1
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  1,4-dihydroquinoxaline 在 四氯苯醌 作用下， 以 乙醇 为溶剂， 反应 10.0h， 生成 [2,3-Bis-(1H-indol-3-yl)-2H-quinoxalin-1-yl]-(2-methoxy-phenyl)-methanone
  参考文献：
  名称：

  Reaction of 1,4-diazines with indoles in the presence of acylating agents

  摘要：

  DOI：

  10.1007/bf02401695
• 作为产物：
  描述：

  1,2,3,4-四氢喹喔啉 在 salcomine 氧气 作用下， 以 乙醇 为溶剂， 反应 24.0h， 以55%的产率得到1,4-dihydroquinoxaline
  参考文献：
  名称：

  Catalytic dehydrogenation of secondary amines with cobalt schiff base complex-oxygen system

  摘要：

  DOI：

  10.1016/s0040-4039(00)80431-1

文献信息

• Synthesis of C5-Allylindoles through an Iridium-Catalyzed Asymmetric Allylic Substitution/Oxidation Reaction Sequence of <i>N</i>-Alkyl Indolines
  作者：Jiamin Lu、Ruigang Xu、Haixia Zeng、Guofu Zhong、Meifang Wang、Zhigang Ni、Xiaofei Zeng

  DOI：10.1021/acs.orglett.1c00810

  日期：2021.5.7

  Iridium/Brønsted acid cooperative catalyzed asymmetric allylic substitution reactions at the C5 position of indolines have been reported for the first time. The highly efficient protocol allows rapid access to various C5-allylated products in good to high yields (48–97%) and enantioselectivities (82% to >99% ee) with wide functional group tolerance. The transformations allow not only the formation

  首次报道了铱/布朗斯台德酸协同催化的二氢吲哚C5位的不对称烯丙基取代反应。高效的协议可以快速获得各种C5烯丙基化的产品，并具有很高的收率（48-97％）和对映选择性（82％到> 99％ee），并且具有宽泛的官能团耐受性。所述转化不仅允许形成C 5-烯丙基吲哚衍生物，而且还允许通过烯丙基化/氧化反应序列以高收率和优异的立体选择性合成C 5-烯丙基吲哚类似物。
• Multitarget Compounds Active at a PPAR and Cannabinoid Receptor
  申请人：Desreumaux Pierre

  公开号：US20110039808A1

  公开（公告）日：2011-02-17

  There is a need for pharmaceutical compounds which have activity at, at least one of a PPAR and a cannabinoid receptor. Thus there are provided such compounds, wherein the compound comprises: a PPAR pharmacophore and a cannabinoid pharmacophore linked together by a moiety comprising a fused bicyclic ring comprising a five membered ring fused with a six membered ring or a six membered ring fused with a six membered ring; wherein the cannabinoid pharmacophore comprises the fused bicyclic ring; and the PPAR pharmacophore comprises a salicylic acid, alkoxybenzylacetic acid or a alkoxyphenylacetic acid functionality; and wherein the PPAR pharmacophore is linked to the bicyclic ring of the cannabinoid pharmacophore through a linker comprising an amine or an amide functional group.

  需要具有至少一种PPAR和大麻受体活性的药物化合物。因此提供了这样的化合物，其中该化合物包括：由包含一个五元环与一个六元环或一个六元环与一个六元环融合的融合双环环的基团连接在一起的PPAR药效团和大麻药效团；其中大麻药效团包括融合双环环；而PPAR药效团包括水杨酸、烷氧基苯乙酸或烷氧基苯乙酸官能团；PPAR药效团通过包含胺基或酰胺官能团的连接物连接到大麻药效团的双环环上。
• HETEROCYCLIC COMPOUNDS, PROCESS FOR PREPARATION OF THE SAME AND USE THEREOF
  申请人：SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES

  公开号：US20170158680A1

  公开（公告）日：2017-06-08

  The present invention provides a heterocyclic compound represented by the formula (I), its stereoisomers, or a pharmaceutically acceptable salt thereof, pharmaceutical compositions thereof, and their use in preparing a medicament for the prevention and/or treatment of central nervous system disease.

  本发明提供了一种由公式（I）表示的杂环化合物，其立体异构体，或其药用可接受的盐，其药物组合物，以及它们用于制备预防或治疗中枢神经系统疾病的药物。
• [EN] 3- AND 6-QUINOLINES WITH N-ATTACHED HETEROCYCLIC CGRP RECEPTOR ANTAGONISTS<br/>[FR] 3- ET 6-QUINOLINES AVEC ANTAGONISTES DE RÉCEPTEURS DE PEPTIDES ASSOCIÉS AU GÈNE DE LA CALCITONINE HÉTÉROCYCLIQUE À N LIAISONS
  申请人：MERCK SHARP & DOHME

  公开号：WO2010021919A1

  公开（公告）日：2010-02-25

  Compounds of Formula (I): (where variables R1A, R1B, R2, R3, R4, A, and Z are as defined herein) which are useful as antagonists of CGRP receptors, and useful in the treatment or prevention of diseases in which CGRP receptors are involved, such as headache, and in particular migraine and cluster headache. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which CGRP receptors are involved.

  公式（I）的化合物：（其中变量R1A、R1B、R2、R3、R4、A和Z的定义如下），这些化合物可用作CGRP受体的拮抗剂，并且在治疗或预防涉及CGRP受体的疾病方面具有用处，例如头痛，特别是偏头痛和集群头痛。本发明还涉及包含这些化合物的药物组合物以及这些化合物和组合物在预防或治疗涉及CGRP受体的这类疾病中的用途。
• ALGINIC ACID DERIVATIVE BONDED TO NONSTEROIDAL ANTI-INFLAMMATORY COMPOUND
  申请人：MOCHIDA PHARMACEUTICAL CO., LTD.

  公开号：US20210000968A1

  公开（公告）日：2021-01-07

  Provided is water-soluble compound that can be used in a sustained-release preparation and is capable of stably releasing a fixed amount of an active ingredient in vivo by using the novel potential base material option of alginic acid as the base material. The present invention relates to an alginic acid derivative having a structure which is obtained by covalently bonding a nonsteroidal anti-inflammatory compound and alginic acid or a salt thereof via a linker, and preferably relates to an alginic acid derivative represented by formula (1) (in the formula: (A) represents one residue derived from alginic acid or a salt thereof and having the C(═O)— group from either L-guluronic acid or D-mannuronic acid, the monosaccharides that constitute alginic acid; (D) represents one residue from a nonsteroidal anti-inflammatory compound; and -L- represents a linker having a functional group which is capable of bonding to (A) by means of an amide bond and having a functional group which is capable of bonding to (D) by means of an ester bond). (D)-L-(A)  (1)

  提供的是一种水溶性化合物，可以用于持续释放制剂，并能够稳定地通过使用新型潜在基材料选项海藻酸作为基材料在体内释放固定量的活性成分。本发明涉及一种通过连接剂以共价键结合非甾体类抗炎化合物和海藻酸或其盐而获得的结构的海藻酸衍生物，优选涉及由式（1）所表示的海藻酸衍生物（在该式中：（A）表示从海藻酸或其盐中派生的一个残基，并且具有构成海藻酸的L-古洛糖酸或D-甘露糖酸中的C(═O)基团的单糖；（D）表示来自非甾体类抗炎化合物的一个残基；以及-L-表示具有能够通过酰胺键与（A）结合的功能基团，并且具有能够通过酯键与（D）结合的功能基团的连接剂）。（D)-L-(A)  (1)